The oral liquid can be used in paediatric patients because it is suitable for those who are unable to swallow capsules and it allows flexible dosing based on bodyweight.
The preparation has approximately 18% increased bioavailability when compared to Prograf capsules.
Modigraf is licensed for the prophylaxis of transplant rejection in kidney, liver or heart allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressant agents.
Modigraf should only be prescribed by those experienced in immunosuppressive therapy and the management of transplant patients.
The MHRA has recently reinforced that the different formulations of tacrolimus are not interchangeable without careful monitoring. They have advised healthcare professionals to:
- be aware of the different bioavailabilities of the available oral formulations
- monitor patients carefully when switching between formulations, or from unlicensed medicines to Modigraf
- take care to prescribe and dispense the correct product/formulation
Further information: Astellas